Cerebrolysin
Also Known As: FPF-1070, Cerebrolysin injection, Porcine brain peptide hydrolysate, Brain peptide mixture, Neurotrophic peptide mixture, EVER Neuro Pharma cerebrolysin, Cerebrolysin infusion, Cerebrolysin neuropeptides, Neurotrophic factor mimetic blend, BDNF NGF mimetic cerebrolysin, Cerebrolysin stroke treatment, neurotrophic peptide, porcine brain extract
Cerebrolysin is a research-grade Porcine brain-derived standardized peptide hydrolysate targeting BDNF/TrkB pathway studied in Immunity & Wellness research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Approved Drug - FDA and/or EMA approved with robust human trial data.
A brain-derived peptide preparation used abroad for stroke and dementia; trial evidence is mixed.
At A Glance
| Category | Immunity & Wellness |
|---|---|
| Compound Class | Porcine brain-derived standardized peptide hydrolysate (<10 kDa peptides); neurotrophic factor mimetic |
| Molecular Target | BDNF/TrkB pathway; NGF/TrkA pathway; anti-apoptotic (Bcl-2 upregulation); antioxidant; glutamate excitotoxicity protection |
| Molecular Weight | mixture |
| Amino Acid Sequence | standardized peptide mixture (<10 kDa) |
| CAS Number | not applicable |
| Half-Life | ~20-30 minutes |
| WADA Status | not_listed |
| Evidence Tier | Approved Drug |
Mechanism Of Action
It delivers a mix of tiny proteins directly to the brain that mimic natural growth signals. These signals protect nerve cells from dying and encourage them to grow new branches.
Studied For
- Acute ischemic stroke recovery
- Traumatic brain injury (TBI)
- Vascular dementia
- Alzheimer's-type dementia
- Cognitive impairment recovery
- Neuroprotection
- Neuroregeneration
- BDNF and NGF pathway stimulation
- Post-stroke rehabilitation
- Parkinson's disease research
- ADHD research
- Memory enhancement
- Anti-apoptotic neuronal protection
- Neuroplasticity promotion
- Spine injury models
- Cerebral ischemia protection
- Age-related cognitive decline
- TBI recovery
- Alzheimer's research
- dementia
- neurogenesis
- stroke recovery
- cognitive decline
- neurological repair
Reported Research Findings
Approved in many countries for stroke, TBI, and dementia. Trial evidence is mixed: some subgroup benefits, but a large stroke trial was negative and a 2020 Cochrane review found insufficient evidence in acute ischemic stroke.
Safety And Handling Notes
Generally tolerated; injection-site reactions, dizziness, agitation, sweating; theoretical porcine allergy.
Contraindicated in hypersensitivity, status epilepticus, and severe renal impairment per foreign labeling. Not FDA-approved.
Regulatory Status
Approved in many EU/Asia/CIS countries; not FDA-approved.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.